|
|
- 2016
Ezrin在三阴性乳腺癌中的表达及意义
|
Abstract:
摘要：目的 研究Ezrin在三阴性乳腺癌中的表达及意义。方法 应用免疫组化SP法测定24例三阴性乳腺癌、58例非三阴性乳腺癌及20例乳腺良性疾病组织中Ezrin的表达，比较各组Ezrin阳性表达率的差异，分析其与三阴性乳腺癌临床病理特征之间的关系。结果 Ezrin在三阴性乳腺癌、非三阴性乳腺癌及乳腺良性疾病组织中的阳性表达率分别为75.00%、48.28%、15.00%，三者比较差异有统计学意义(P<0.01)。三阴性乳腺癌中Ezrin高表达与组织学分级和临床TNM分期有关(P<0.05)，而与患者年龄、肿瘤大小及腋窝淋巴结转移状况无关(P>0.05)。结论 Ezrin在三阴性乳腺癌中高表达，提示其可以作为三阴性乳腺癌预后不良的一个重要指标。
ABSTRACT: Objective To study the expression and significance of Ezrin in triple negative breast cancer tissues. Methods We selected 102 cases, including 24 ones of triple negative breast cancer, 58 ones of non-triple negative breast cancer, and 20 of benign breast disease. The expression of Ezrin in all the specimens was detected by SP immunohistochemistry. We observed whether there was any difference between the positive expression rates of Ezrin in the three groups. We also analyzed the correlation between Ezrin expression and clinicopathologic parameters of triple negative breast cancer. Results The positive expression rate of Ezrin in groups of triple negative breast cancer, non-triple negative breast cancer, and benign breast disease was 15.00%, 48.28% and 75.00%, respectively. The difference between the three groups differed significantly (P<0.01). The high expression of Ezrin in triple negative breast cancer had relationship with histological grading and clinical TNM staging (P<0.05), but not with patients’ age, tumor size, or axillary lymph node metastasis (P>0.05). Conclusion Ezrin is highly expressed in triple negative breast cancer tissues; therefore, it can be used as an important indicator of poor prognosis of triple negative breast cancer
| [1] | 马力，张祥宏，邢凌霄，等. Ezrin与乳腺浸润性导管癌发生发展及预后的关系[J]. 中华肿瘤杂志, 2008, 30(4):279-283. |
| [2] | GSCHWANTLER-KAULICH D, NATTER C, STEURER S, et al.Increase in ezrin expression from benign to malignant breast tumours[J]. Cell Oncol (Dordr), 2013, 36(6):485-491. |
| [3] | YADAV BS, CHANANA P, JHAMB S. Biomarkers in triple negative breast cancer: A review[J]. World J Clin Oncol, 2015, 6(6):252-263. |
| [4] | LI L, WANG YY,ZHAO ZS, et al. Ezrin is associated with gastric cancer progression and prognosis[J]. Pathol Oncol Res, 2011, 17(4):909-915. |
| [5] | CLUCAS J, VALDERRAMA F. ERM proteins in cancer progression[J]. J Cell Sci, 2014, 127(Pt2):267-275. |
| [6] | 李琼，吴明富，宋安萍，等. 浸润性乳腺导管癌组织中Ezrin和钙粘素E的表达与淋巴结转移的关系[J]. 癌症, 2006, 25(3):363-366. |
| [7] | 陈竟男，王杨，金东辉，等. miR-18b增强乳腺癌MDA-MB-231细胞对顺铂化疗敏感性的作用及其机制[J]. 吉林大学学报(医学版), 2015, 41(2):316-320. |
| [8] | 王明喜，郑荣生，承泽农，等. 埃兹蛋白在乳腺癌中的表达及意义[J]. 蚌埠医学院学报, 2013, 38(7):809-812. |
| [9] | ELLIOTT BE, MEENS JA, SENGUPTA SK, et al.The membrane cytoskeleton crosslinker Ezrin is required for metastasis of breast carcinoma cells[J]. Breast Cancer Res, 2005, 7(3):365-373. |
| [10] | LI Q, GAO H, XU H, et al.Expression of ezrin correlates with malignant phenotype of lung cancer, and in vitro knockdown of ezrin reverses the aggressive biological behavior of lung cancer cells[J]. Tumour Biol, 2012, 33(5):1493-1504. |
| [11] | NAVRATIL J, FABIAN P, PALACOVA M, et al. Triplenegative breast cancer[J]. Klin Onkol, 2015, 28(6):405-415. |
| [12] | 方军. Ezrin蛋白表达与乳腺癌临床病理特征的相关性研究[J]. 检验医学与临床, 2014, 11(8):1048-1049. |
| [13] | MAK H, NABA A, VARMA S, et al.Ezrin phosphorylation on tyrosine 477 regulates invasion and meta-stasis of breast cancer cells[J]. BMC Cancer, 2012, 12(1):82-96. |
| [14] | LI Q, WU M, WANG H, et al. Ezrin silencing by small hairpin RNA reverses metastatic behaviors of human breast cancer cells[J].Cancer Lett,2008, 261(1):55-63. |
| [15] | HURVITZ S, MEAD M. Triple-negative breast cancer: advancements in characterization and treatment approach[J]. Curr Opin Obstet Gynecol, 2016, 28(1):56-69. |
